Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
The aggregate gross proceeds from this offering are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the offering.
- The aggregate gross proceeds from this offering are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the offering.
- The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant.
- The offering is expected to close on or about May 29, 2024, subject to the satisfaction of customary closing conditions.
- All of the shares of common stock and pre-funded warrants to be sold in the offering are being sold by Perspective.